Correlation Between Dupont De and SOCGEN
Specify exactly 2 symbols:
By analyzing existing cross correlation between Dupont De Nemours and SOCGEN 3337 21 JAN 33, you can compare the effects of market volatilities on Dupont De and SOCGEN and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dupont De with a short position of SOCGEN. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dupont De and SOCGEN.
Diversification Opportunities for Dupont De and SOCGEN
Very good diversification
The 3 months correlation between Dupont and SOCGEN is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Dupont De Nemours and SOCGEN 3337 21 JAN 33 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SOCGEN 3337 21 and Dupont De is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dupont De Nemours are associated (or correlated) with SOCGEN. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SOCGEN 3337 21 has no effect on the direction of Dupont De i.e., Dupont De and SOCGEN go up and down completely randomly.
Pair Corralation between Dupont De and SOCGEN
Allowing for the 90-day total investment horizon Dupont De Nemours is expected to generate 0.75 times more return on investment than SOCGEN. However, Dupont De Nemours is 1.34 times less risky than SOCGEN. It trades about 0.03 of its potential returns per unit of risk. SOCGEN 3337 21 JAN 33 is currently generating about 0.01 per unit of risk. If you would invest 6,814 in Dupont De Nemours on September 3, 2024 and sell it today you would earn a total of 1,545 from holding Dupont De Nemours or generate 22.67% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 11.52% |
| Values | Daily Returns |
Dupont De Nemours vs. SOCGEN 3337 21 JAN 33
Performance |
| Timeline |
| Dupont De Nemours |
| SOCGEN 3337 21 |
Dupont De and SOCGEN Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Dupont De and SOCGEN
The main advantage of trading using opposite Dupont De and SOCGEN positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dupont De position performs unexpectedly, SOCGEN can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SOCGEN will offset losses from the drop in SOCGEN's long position.| Dupont De vs. SPACE | Dupont De vs. Bayview Acquisition Corp | Dupont De vs. T Rowe Price | Dupont De vs. Ampleforth |
| SOCGEN vs. Boston Properties | SOCGEN vs. Live Ventures | SOCGEN vs. Mid Atlantic Home Health | SOCGEN vs. CVW CleanTech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Complementary Tools
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |